Giammaria Fiorentini1,1, Andrea Mambrini2,2, Donatella Sarti1,1, Maurizio Cantore3,3, Luca Mulazzani4,4, Gian Maria Mattioli4,4, Stefano Guadagni5,5. 1. Oncology Unit, Azienda Ospedaliera "Ospedali Riuniti Marche Nord", 61122 Pesaro, Italy. 2. Oncology Unit, Carrara General Hospital, Carrara, Italy. 3. Oncology Unit, Azienda Ospedaliera Carlo Poma, Mantova, Italy. 4. Diagnostics for Images Unit & Interventional Radiology, Azienda Ospedaliera "Ospedali Riuniti Marche Nord", 61122 Pesaro, Italy. 5. Department of Applied Clinical Sciences and Biotechnology, Section of General Surgery, University of L'Aquila, via Vetoio 67100 L'Aquila, Italy.
Abstract
AIM: The aim is to report clinical outcomes of hepatic intra-arterial (IACHT) and systemic chemotherapy (SCHT), followed by gemcitabine-based maintenance therapy (maintenance), for the treatment of relapsed or unresectable cholangiocarcinoma. PATIENTS & METHODS: In this retrospective observational study, 145 cholangiocarcinoma patients were treated with Epirubicin-Cisplatin as IACHT associated with Capecitabine or 5-fluorouracil as SCHT. Maintenance was performed with gemcitabine-based schedule. Toxicity was assessed with NCI-CTCAE and tumor response with RECIST 1.1. RESULTS: Tumor response was complete in 1%, partial in 20%, stable disease in 48% and progression in 31% of patients (3 months after therapy). The most frequent adverse events were: anemia (24%), nausea and vomiting (33%), alopecia (60%). CONCLUSION: Cholangiocarcinoma patients may benefit from IAHCT-SCHT. Maintenance may prolong clinical benefits. ClinicalTrials.gov registry Identifier: NCT01920503.
AIM: The aim is to report clinical outcomes of hepatic intra-arterial (IACHT) and systemic chemotherapy (SCHT), followed by gemcitabine-based maintenance therapy (maintenance), for the treatment of relapsed or unresectable cholangiocarcinoma. PATIENTS & METHODS: In this retrospective observational study, 145 cholangiocarcinoma patients were treated with Epirubicin-Cisplatin as IACHT associated with Capecitabine or 5-fluorouracil as SCHT. Maintenance was performed with gemcitabine-based schedule. Toxicity was assessed with NCI-CTCAE and tumor response with RECIST 1.1. RESULTS: Tumor response was complete in 1%, partial in 20%, stable disease in 48% and progression in 31% of patients (3 months after therapy). The most frequent adverse events were: anemia (24%), nausea and vomiting (33%), alopecia (60%). CONCLUSION: Cholangiocarcinoma patients may benefit from IAHCT-SCHT. Maintenance may prolong clinical benefits. ClinicalTrials.gov registry Identifier: NCT01920503.
Authors: Juan Valle; Harpreet Wasan; Daniel H Palmer; David Cunningham; Alan Anthoney; Anthony Maraveyas; Srinivasan Madhusudan; Tim Iveson; Sharon Hughes; Stephen P Pereira; Michael Roughton; John Bridgewater Journal: N Engl J Med Date: 2010-04-08 Impact factor: 91.245
Authors: Gennaro Nuzzo; Felice Giuliante; Francesco Ardito; Agostino Maria De Rose; Maria Vellone; Gennaro Clemente; Carlo Chiarla; Ivo Giovannini Journal: Updates Surg Date: 2010-08
Authors: Niraj J Gusani; Fady K Balaa; Jennifer L Steel; David A Geller; J Wallis Marsh; Albert B Zajko; Brian I Carr; T Clark Gamblin Journal: J Gastrointest Surg Date: 2007-09-11 Impact factor: 3.452
Authors: Thomas Walter; Anne M Horgan; Mairead McNamara; Liz McKeever; Trisha Min; David Hedley; Stefano Serra; Monika K Krzyzanowska; Eric Chen; Helen Mackay; Ronald Feld; Malcolm Moore; Jennifer J Knox Journal: Eur J Cancer Date: 2012-09-01 Impact factor: 9.162
Authors: T Okusaka; K Nakachi; A Fukutomi; N Mizuno; S Ohkawa; A Funakoshi; M Nagino; S Kondo; S Nagaoka; J Funai; M Koshiji; Y Nambu; J Furuse; M Miyazaki; Y Nimura Journal: Br J Cancer Date: 2010-07-13 Impact factor: 7.640